Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | FNTA | P49354 | 1/20 | 0.38 |
| ▸ | FNTB | P49356 | 1/20 | 0.38 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4845870 | 0.91 | TAAR1 (0.41) | TAAR1FNTAFNTBPGGT1BHRH3 | |
| SCHEMBL5258759 | 0.82 | NPC1 (0.38) | — | |
| SCHEMBL4834899 | 0.81 | MMP2 (0.43) | — | |
| SCHEMBL5259949 | 0.81 | NPC1 (0.39) | — | |
| SCHEMBL5255054 | 0.81 | MAP3K8 (0.38) | — | |
| SCHEMBL5259468 | 0.80 | NPC1 (0.34) | — | |
| SCHEMBL4842422 | 0.80 | TAAR1 (0.47) | TAAR1 | |
| SCHEMBL5257452 | 0.79 | NPC1 (0.34) | — | |
| SCHEMBL5259906 | 0.79 | LMNA (0.43) | — | |
| SCHEMBL5258008 | 0.78 | HPSE (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100358893-C | Certain novel imidazopyridines and uses thereof | ASTRAZENECA AB (SE) | 2008-01-02 | — | — | CN | claimed |
| EP-1539759-B1 | NOVEL IMIDAZOPYRIDINES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-08-15 | — | — | EP | claimed |
| US-20050261333-A1 | Use of and some novel imidazopyridines | ASTRAZENECA A B (SE) | 2005-11-24 | — | — | US | claimed |
| CN-1684964-A | Use of and some novel imidazopyridines | ASTRAZENECA AB (SE) | 2005-10-19 | — | — | CN | claimed |
| US-7410966-B2 | Use of and some novel imidazopyridines | ASTRAZENECA AB (SE) | 2008-08-12 | — | — | US | disclosed |
| CN-100358893-C | Certain novel imidazopyridines and uses thereof | ASTRAZENECA AB (SE) | 2008-01-02 | — | — | CN | disclosed |
| EP-1539759-B1 | NOVEL IMIDAZOPYRIDINES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-08-15 | — | — | EP | disclosed |
| US-20050261333-A1 | Use of and some novel imidazopyridines | ASTRAZENECA A B (SE) | 2005-11-24 | — | — | US | disclosed |
| CN-1684964-A | Use of and some novel imidazopyridines | ASTRAZENECA AB (SE) | 2005-10-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261333-A1 | Use of and some novel imidazopyridines | ITK, CSNK1A1, RPS6KA1 | TAAR1 2145/4885FNTA 4054/4885FNTB 4162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.